Optimising Perioperative Outcomes: A Practical Guide to Cardiac Biomarkers in Noncardiac Surgery
The 2025 Expert Consensus on cardiac biomarkers strongly recommends using hs-cTn, often combined with BNP/NT-proBNP, for both preoperative risk assessment and postoperative surveillance (daily for 48-72 hours) in high-risk...
Related Links
- ACC 2025 Spotlight: DROP-Asian ACS Interim Analysis Highlights Regional Gains in NSTEMI Care
- STRONG-HF Japan Study
- Implementing 0/1-Hour Algorithm using High-Sensitivity Cardiac Troponin in the Emergency Department
- Every Heartbeat Counts: Take Action & Make an Impact This World Heart Day
- The effectiveness of telemonitoring and integrated personalised diabetes management in people with insulin-treated type 2 diabetes mellitus
- Chinese expert consensus on the risk assessment and management of panvascular disease in patients with type 2 diabetes mellitus (2022 edition)
- STRONG-HF: Enhancing GDMT regimen in Asia
- Implementation of STRONG-HF protocol in heart failure management: an Australian perspective
- Unleashing the Power of STRONG-HF: Enabling Transformation in Heart Failure Management Across China
- Reshaping HF Management at NHCS
- Screening & Diagnosis of Heart Failure in Pre-Diabetic and Diabetic Patients
- Elevating CVD management in APAC to its Zenith- with Cardiac biomarkers
- STRONG-HF: Rapid Uptitration of Guideline Directed Medical Therapy for Heart Failure
- Guidelines Interpretation – Guidelines for the management of chronic heart failure in dialysis patients in China
- Heart failure management in Australia and the role of NT-proBNP in monitoring and treatment
- Download APAC STRONG-HF Master Pack: First-hand Insights from Prof Mebazaa on Heart Failure Treatment Monitoring
- Heart Failure Management in India – Overcoming Present Challenges
- STRONG-HF Trial highlighting benefits of treatment optimisation
- STRONG-HF: Implementation of GDMT Heart Failure Therapy & Post-discharge Heart Failure Management
- Uncovering the Cardio-renal Risks of Chinese T2DM patients: Back to the Future with CUHK!
- Management of Diabetes in Japan – Can Patients Play a More Significant Role?
- T2DM Patient Support Program in Hong Kong and the Value of NT-proBNP
- Rapid algorithms for hs-cTn in ED: Boon or Bane?
- 2021 ESC Heart Failure Guidelines: What’s new?
- Heart Failure in Hong Kong- Present Challenges and Future Strategies
- Rapid Algorithms for Faster Triage of ED Patients with Suspected AMI – What Are We Waiting For?
- Digital Prediction Platforms: A catalyst towards personalized CVD prognosis
- CVD Management in T2DM – JCS and JDS Joint Consensus
- ESC Recommendation: High sensitivity troponin assay vs conventional assay
- ESC Recommendation: Rapid algorithms using hs troponin in ED
- Setting sight on breakthrough diagnostics
- Recommendations of IFCC on Natriuretic Peptide Testing
- How to Implement ESC Rapid Algorithm Successfully?
- The Changes in Rapid Algorithms for Acute Coronary Syndrome
- Sex Differences in Troponin Levels – affecting high-sensitivity cardiac troponin (hs-cTn) levels
- DAPA-HF and EMPEROR-Reduced Study Highlights
- The role of biomarkers in HF
- Digital health in HF management
- Summary of APSC High Sensitivity Troponin T Consensus
- APSC hs-TnT Consensus & Future Use of Biomarker in T2DM & COVID-19
- Management of Cardiovascular Risks of COVID-19 Patients
- Management of COVID-19 and the Heart, Experience from Front Line